Shona Hendry1,2, David J Byrne1, Michael Christie3, Daniel P Steinfort4,5, Louis B Irving4, Carrie-Anne Wagner4, Timothy Ellwood6, Wendy A Cooper6,7,8, Stephen B Fox1,9. 1. Department of Pathology at Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 2. Department of Pathology at St Vincent's Hospital, Melbourne, VIC, Australia. 3. Department of Pathology at Royal Melbourne Hospital, Melbourne, VIC, Australia. 4. Department of Respiratory & Sleep Medicine, Royal Melbourne Hospital, Melbourne, VIC, Australia. 5. Department of Medicine (RMH), University of Melbourne, Melbourne, VIC, Australia. 6. Sydney Medical School, University of Sydney, Sydney, NSW, Australia. 7. Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia. 8. School of Medicine, Western Sydney University, Sydney, NSW, Australia. 9. Department of Medical Oncology at the University of Melbourne, Melbourne, VIC, Australia.
Abstract
OBJECTIVES: PD-L1 immunohistochemistry (IHC) is an essential predictive biomarker for patients with non-small cell lung cancer (NSCLC), required to inform treatment decisions regarding anti-PD-1 immune checkpoint inhibitor therapy. This study aims to investigate the concordance between PD-L1 IHC assessed on NSCLC cytology and histology specimens and to determine the impactce of tumour cellularity. METHODS: Matched cytology and histology NSCLC specimens were retrieved from the archives of the Royal Melbourne Hospital and the Royal Prince Alfred Hospital. PD-L1 IHC was performed concurrently on both specimens at the Peter MacCallum Cancer Centre using the SP263 assay kit on the Ventana Benchmark Ultra staining platform and scored by two experienced pathologists. RESULTS: Overall agreement between matched cytology and histology specimens was good (intraclass correlation coefficient = 0.653, n = 58); however, markedly increased when the analysis was limited to cell-blocks with >100 tumour cells (intraclass correlation coefficient = 0.957, n = 29). Specificity at both 1% and 50% cut-offs was high regardless of cellularity; however, sensitivity decreased in samples with <100 tumour cells. CONCLUSIONS: PD-L1 IHC on cytology cell-block specimens in NSCLC is an acceptable alternative to histological specimens, provided adequate tumour cells are present. Clinicians and pathologists should be mindful of the risk of false negative PD-L1 IHC in samples with low tumour cellularity, to avoid excluding patients from potentially beneficial treatment.
OBJECTIVES:PD-L1 immunohistochemistry (IHC) is an essential predictive biomarker for patients with non-small cell lung cancer (NSCLC), required to inform treatment decisions regarding anti-PD-1 immune checkpoint inhibitor therapy. This study aims to investigate the concordance between PD-L1 IHC assessed on NSCLC cytology and histology specimens and to determine the impactce of tumour cellularity. METHODS: Matched cytology and histology NSCLC specimens were retrieved from the archives of the Royal Melbourne Hospital and the Royal Prince Alfred Hospital. PD-L1 IHC was performed concurrently on both specimens at the Peter MacCallum Cancer Centre using the SP263 assay kit on the Ventana Benchmark Ultra staining platform and scored by two experienced pathologists. RESULTS: Overall agreement between matched cytology and histology specimens was good (intraclass correlation coefficient = 0.653, n = 58); however, markedly increased when the analysis was limited to cell-blocks with >100 tumour cells (intraclass correlation coefficient = 0.957, n = 29). Specificity at both 1% and 50% cut-offs was high regardless of cellularity; however, sensitivity decreased in samples with <100 tumour cells. CONCLUSIONS:PD-L1 IHC on cytology cell-block specimens in NSCLC is an acceptable alternative to histological specimens, provided adequate tumour cells are present. Clinicians and pathologists should be mindful of the risk of false negative PD-L1 IHC in samples with low tumour cellularity, to avoid excluding patients from potentially beneficial treatment.
Authors: Mohammed S I Mansour; Kajsa Ericson Lindquist; Tomas Seidal; Ulrich Mager; Rikard Mohlin; Lena Tran; Kim Hejny; Benjamin Holmgren; Despoina Violidaki; Katalin Dobra; Annika Dejmek; Maria Planck; Hans Brunnström Journal: Acta Cytol Date: 2021-07-07 Impact factor: 2.319
Authors: Lucia Roa-Peña; Sruthi Babu; Cindy V Leiton; Maoxin Wu; Sofia Taboada; Ali Akalin; Jonathan Buscaglia; Luisa F Escobar-Hoyos; Kenneth R Shroyer Journal: Cancer Cytopathol Date: 2021-06-02 Impact factor: 4.264
Authors: Steven Bozinovski; Amanda Vannitamby; Kanishka Rangamuwa; Savreet Aujla; Hao Wang; Christian Aloe; Louis Irving; Tracy T Leong; Daniel P Steinfort Journal: Transl Lung Cancer Res Date: 2021-06